Table 3.
Main medical treatment of CD and UC
| Treatment | Number of patients (%) | ||
|---|---|---|---|
| CD (n = 113) | UC (n = 30) | IBD (n = 143) | |
| Induction therapy | |||
| Corticosteroids | 57 (50.4) | 18 (60.0) | 75 (52.4) |
| Mesalazine | 29 (25.7) | 25 (83.3) | 54 (37.8) |
| Biological agent | 65 (45.5) | 5 (16.7) | 70 (49.0) |
| Thalidomide | 14 (12.4) | 3 (10.0) | 17 (11.9) |
| Maintenance therapya | |||
| Azathioprine | 54 (47.8) | 6 (20.0) | 60 (42.0) |
| Biological agent | 48 (42.5) | 2 (6.7) | 50 (35.0) |
| Thalidomide | 32 (28.3) | 3 (10.0) | 35 (24.5) |
| Mesalazine | 23 (20.4) | 21 (70.0) | 44 (30.8) |
| Methotrexate | 3 (2.7) | 0 | 3 (2.1) |
| Cyclosporine A | 2 (1.8) | 0 (0.0) | 2 (1.4) |
| Total enteral nutrition | 2 (1.8) | 0 (0.0) | 2 (1.4) |
| Corticosteroids | 31 (27.4) | 11 (36.7) | 42 (29.4) |
aThe data are from an analysis of the first year of maintenance therapy